East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Etyqa (Estradiol and Norethindrone Acetate Tablets USP), 0.5 mg/0.1 mg and 1 mg/0.5 mg. Aurobindo Pharma’s Etyqa (Estradiol and Norethindrone Acetate Tablets USP), are an AB-rated generic equivalent to the reference listed drug (RLD), Activella® Tablets manufactured by Amneal Pharmaceuticals LLC.

Etyqa (Estradiol and Norethindrone Acetate Tablets USP) are indicated for:

• Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause
• Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy due to Menopause
• Prevention of Postmenopausal Osteoporosis.